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Abstract
Background: The p23.2 region of human chromosome 8 is frequently deleted in several types of
epithelial cancer and those deletions appear to be associated with poor prognosis. Cub and Sushi
Multiple Domains 1 (CSMD1) was positionally cloned as a candidate for the 8p23 suppressor but
point mutations in this gene are rare relative to the frequency of allelic loss. In an effort to identify
alternative mechanisms of inactivation, we have characterized CSMD1 expression and epigenetic
modifications in head and neck squamous cell carcinoma cell lines.
Results: Only one of the 20 cell lines examined appears to express a structurally normal CSMD1
transcript. The rest express transcripts which either lack internal exons, terminate abnormally or
initiate at cryptic promoters. None of these truncated transcripts is predicted to encode a
functional CSMD1 protein. Cell lines that express little or no CSMD1 RNA exhibit DNA
methylation of a specific region of the CpG island surrounding CSMD1's first exon.
Conclusion: Correlating methylation patterns and expression suggests that it is modification of
the genomic DNA preceding the first exon that is associated with gene silencing and that
methylation of CpG dinucleotides further 3' does not contribute to inactivation of the gene. Taken
together, the cell line data suggest that epigenetic silencing and aberrant splicing rather than point
mutations may be contributing to the reduction in CSMD1 expression in squamous cancers. These
mechanisms can now serve as a focus for further analysis of primary squamous cancers.

Background
CUB and Sushi Multiple Domains 1 (CSMD1) was cloned as
a candidate tumor suppressor or progression gene from a
region of human chromosome 8 deleted in tumors of the
upper aerodigestive tract, prostate, ovary and bladder [17]. Deletion of 8p23.2 or reduced expression of CSMD1
has been associated with poor prognosis in head and neck
squamous cell carcinomas and in prostate cancers [2,5,8].

CSMD1, consisting of 70 exons spread over two megabases of 8p23.2, encodes a rare 11.5 kb transcript most
abundantly expressed in the brain [1]. It is the founding
member of a novel, evolutionarily highly conserved gene
family whose proteins contain multiple domains thought
to be sites of protein-protein or protein-ligand interactions and whose structure suggests that they may be transmembrane receptors or adhesion proteins [9,10].
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Positions
Figure 1 of the amplicons used for COBRA and bisulfite sequencing relative to CSMD1's first exon and the CpG island
Positions of the amplicons used for COBRA and bisulfite sequencing relative to CSMD1's first exon and the CpG island. Amplicon 1 extends from -395 to -112 bp, amplicon 2 from +175 to +396 bp, and amplicon 3 from +398 to +718 bp relative to the
first base of the transcript. The region between amplicons 1 and 2 is so GC rich that no workable PCR primers could be
designed to amplify it after bisulfite conversion. Transcription of CSMD1 is from left to right in the figure.

Tumor suppressor genes are expected to be inactivated in
cancers either genetically by mutations or epigenetically
by modification of their promoters. While CSMD1 transcripts are detectable in upper aerodigestive tract epithelium, preliminary analysis of several head and neck
squamous cell carcinoma cell lines suggested that CSMD1
expression was lost in these lines [1]. Although the region
containing CSMD1 is frequently deleted in head and neck
squamous cell carcinomas and prostatic adenocarcinomas [3,11-15], point mutations in the gene are relatively
rare in primary squamous cancers [16] and in squamous
cell carcinoma cell lines (Schmidt, Richter and Scholnick,
unpublished). Nonsense or splice junction mutations in
CSMD1 have not been reported and not enough is known
about the function of the protein to accurately assess the
effect of the few missense mutations that have been
detected. Thus, if CSMD1 is inactivated in tumors, alternative mechanisms for gene silencing must be operating.
In this paper, we demonstrate that while most squamous
cell carcinoma cell lines do not express full length CSMD1
transcripts, nearly all produce abnormal transcripts
unlikely to encode functional CSMD1 proteins. Methylation of the DNA preceding CSMD1's first exon is correlated with reduction in the level of expression and cell
lines expressing at low levels do not appear to elongate the
full 11.5 kb transcript. Other anomalies of expression
include incorrect splicing and the use of cryptic promoters. Our data suggest that activation of these promoters
may result from the global demethylation of the genome
associated with tumorigenesis (reviewed by Ehrlich [17]).

Taken together these data demonstrate that mechanisms
other than point mutation are responsible for the aberrant
CSMD1 expression in head and neck squamous cell carcinoma cell lines, and these data suggest potential targets
for further investigation in primary tumors.

Results
CSMD1 promoter methylation in HNSCC cell lines is
correlated with expression levels
Preliminary evidence suggested that CSMD1 expression is
lost in head and neck squamous cell carcinomas [1] but
that point mutations were rare [[16], and Schmidt, Richter
and Scholnick, unpublished]. To date, only two of the 20
cell lines we have tested for CSMD1 expression,
UPCI:SCC066 and PCI-13, express large transcripts initiated at the normal CSMD1 promoter. These data suggest
that a mechanism(s) other than point mutation must be
responsible for the loss of expression. CSMD1's first exon
is embedded in a 3.7 kb CpG island (data from the UCSC
genome browser [18]) suggesting that promoter methylation might epigenetically silence the gene. To test this
hypothesis, we surveyed 32 head and neck cancer cell
lines for CSMD1 promoter methylation using the Combined Bisulfite Restriction Analysis (COBRA) technique
described by Xiong and Laird (Methods) [19]. COBRA
analysis of the three amplicons diagrammed in Figure 1
suggested that 28 of the cell lines (87%) had more promoter methylation than did normal upper aerodigestive
epithelium (data not shown).

We selected nine of these cell lines for high resolution
analysis of promoter methylation by sequencing of clones
from bisulfite converted genomic DNA. This approach has
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Figure 2 status of each of the 19 CpG dinucleotides in amplicon 1
Methylation
Methylation status of each of the 19 CpG dinucleotides in amplicon 1. Each CpG dinucleotide within the amplicon is represented by a column and its position in base pairs relative to the CpG island is given at the top of the figure. Positions were
measured from the end of the CpG nearest the 5' end of CSMD1 as defined by data obtained from the UC Santa Cruz genome
browser (island sequence beginning CGGTGTGCGGCGTGAGCTTCCCCCACCCGAG...). Each sequenced clone is represented by a row and is numbered sequentially starting from the top of the figure. Open symbols (❍) indicate that cytosine residue of the dinucleotide was unmethylated, closed symbols (●) indicate that it was methylated, and "x" indicates that the
identity of the base could not be determined from that sequencing reaction. The level of expression is presented as a percentage relative to five pooled samples of normal UPPP epithelium. These are not the same UPPP samples used for measurement of
promoter methylation in normal tissue. A) normal oropharyngeal epithelium from five individuals undergoing uvulopalatopharyngoplasty. B) Methylation status of two cell lines that express large CSMD1 transcripts from the normal promoter (PCI13 and UPCI:SCC066), C) cell lines with low expression of the CSMD1 transcript from the normal promoter (PCI-2, PCI-1,
PCI-100, 094, 041, UPCI:SCC056, and UPCI:SCC104).
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the distinct advantage of allowing determination of the
state of all the CpG dinucleotides within an amplicon on
an allele by allele basis. Amplicons 1 and 2 have 19 and
20 CpG dinucleotides, respectively. Amplicon 3 could not
be examined by this technique because it is unclonable
after bisulfite conversion. The methylation data were correlated to CSMD1 expression levels as measured by quantitative RT-PCR using an amplicon spanning exons 1 and
2 (Methods). A pool of cDNA from five normal oropharyngeal epithelium specimens served as a basis for comparison to the cell lines.
Our data from amplicon 1 demonstrate a clear relationship between methylation and the level of expression
(Figure 2). The bisulfite sequencing data confirm that
there is relatively little promoter methylation in normal
tissue (clones 1–20, Figure 2A). This is also the case in cell
line UPCI:SCC066 which expresses a large CSMD1 transcript from the normal promoter at a level approximately
33% of that of normal tissue (clones 32–39, Figure 2B).
PCI-13, our highest expressing line at 125% of normal
epithelium, displays two distinct patterns of promoter
methylation with some clones heavily methylated (clones
21–24, and 30) and others with no methylation (clones
25–39 and 31; Figure 2B). This pattern is consistent with
either heterozygosity for methylation or the co-existence
of 2 distinct populations within the cell line, one heavily
methylated and one unmethylated. We cannot distinguish between these two possibilities using the currently
available data.
The remaining cell lines express CSMD1 at a level half that
of UPCI:SCC066 or less (ranging from 17% to 1% of normal epithelium) and they exhibit considerably greater
methylation of amplicon 1 (clones 40–76, Figure 2C).
Cell lines with more amplicon 1 methylation tend to
express the gene at lower levels but the relationship is not
strictly quantitative (Figure 2C).
In contrast, our data revealed no relationship between
expression level and methylation of amplicon 2 (located
towards the 3' end of exon 1, Figure 1). For example, all of
the 10 clones of amplicon 2 sequenced from PCI-13 were
methylated at 19 or 20 of their 20 CpG dinucleotides.
UPCI:SCC066, on the other hand, has nearly no methylation in amplicon 2 with only a single methylated CpG
dinucleotide detected in one clone out of the nine
sequenced. Amplicon 2 ranges from completely unmethylated to heavily methylated in the seven remaining cell
lines (data not shown).
Low transcript levels are accompanied by a failure to
elongate the full CSMD1 transcript
On the surface, the quantitative RT-PCR data presented in
Figure 2 suggest that the cell lines we consider low
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expressing might still have up to 17% of the normal level
of CSMD1 transcript. A survey of 20 cell lines using a battery of RT-PCR primer pairs located throughout the 11.5
kb transcript reveals that this is not the case. These lines
included OKF6-TERT1, a TERT immortalized, p16 deficient but untransformed oral keratinocyte cell line [20].
Our data suggest that the low expressing cell lines shown
in Figure 2C express considerably more of the 5' end of the
11.5 kb transcript than they do exons further 3', a phenomenon well illustrated by cell line PCI-100. This line
expresses the exon 1/exon 2 amplicon at approximately
15% of the level of normal epithelium. In contrast, we
had previously reported that CSMD1 transcripts were not
detectable in this line by combined RT-PCR and Southern
blotting using three sets of intron spanning primers [1].
The most 5' of those amplicons spans exons 9 through 26.
Analysis with additional primer pairs resolves this apparent paradox by demonstrating that the amount of transcript declines sharply and reproducibly as one examines
progressively more 3' exons (Figure 3). The same effect is
seen using either oligo-dT or random hexamer primed
cDNA. No transcript of this structure has been detected in
normal epithelium nor have we detected any sequence
alterations in PCI-100 that would explain why the full
transcript is not expressed. It is not clear whether PCI-100
produces a small number of discrete size classes of transcript, if individual transcripts terminate at random points
within the very large introns in this part of the gene (the
first 10 introns average ~150 kb in length), or if the short
transcripts result from the elevated activity of a previously
undetected posttranscriptional control mechanism.
Inactivation of CSMD1 by aberrant splicing
Two cell lines, UPCI:SCC066 and PCI-13, express large
CSMD1 transcripts initiated at the normal promoter. Subsequent finer scale analysis demonstrates that PCI-13's
transcript lacks exons 4 and 5, resulting in a frameshiftinduced nonsense codon in exon 6 (Figure 4). Sequencing
of the PCI-13 RT-PCR product demonstrates the direct
juxtaposition of wildtype exons 3 and 6 and that the transcript contains no novel sequences or splices that would
prevent the frameshift. UPCI:SCC066 produces two
transcripts, a normal one that includes exons 4 and 5 and
another that lacks them (Figure 4). RT-PCR of human fetal
brain cDNA reveals very low levels of an RT-PCR product
corresponding in size to that expected from the internally
deleted transcript. This band is not readily visible at the
exposure used for Figure 4A. We have not detected a similar sized PCR product in RNA from oropharyngeal
epithelium but this may reflect the fact that CSMD1 transcripts are ~10x less abundant in oropharyngeal epithelium than they are in fetal brain (data not shown).
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ticular, retention of sequences from intron 40 is common.
The high frequency of faulty splicing may explain the
broadness of the 6.4 kb CSMD1 band in Figure 5A and
suggests that the 8.7 kb transcript may also be incompletely or improperly spliced.

Figure 3
RT-PCR
CSMD1
transcripts
data demonstrating
in cell linethe
PCI-100
preferential loss of longer
RT-PCR data demonstrating the preferential loss of longer
CSMD1 transcripts in cell line PCI-100. Exons 1 and 2 were
amplified with prm1542 (gggacccgatgctatgagagggaag) and
prm1482 (cccgtgaggaaaccctgggctct), exons 2 through 4 with
prm2078 (gggcgagcgcaataggatacagtt) and prm1382 (ggatggcgtggccttccaagatgtag), exons 4 through 6 with prm1392 (agctgcctccctggctacatcttgg) and prm1405
(cttggaactgagcgttaaatcctttg), and exons 7 through 11 with
prm1463 (tgaaaaaggcgattgagttgaagtc) and prm1421 (gaccgatctggtgtctcccaccttc). "STD" indicates a lane of DNA standards whose sizes are given on the left side of the figure,
"HFB" = human fetal brain, "blank" indicates a control reaction with water substitute for cDNA.

The transcripts lacking exons 4 and 5 appear to result from
aberrant splicing rather than somatic deletion of these two
exons or mutations of their splicing consensus sequences.
Exons 4 and 5 can be amplified from PCI-13 genomic
DNA and sequencing of those PCR products demonstrates
that both their coding sequences and consensus splice
sites are wildtype.
Activation of cryptic promoters in cancer cell lines
The RT-PCR survey revealed a second transcriptional
anomaly exhibited by 4 cell lines: SCC9, 041, PCI-1 and
PCI-2. Like PCI-100, these lines express low levels of the
very 5' end of the transcript and even lower levels of more
3' exons within the first half of the transcript. However,
these lines are distinct in expressing higher levels of the 3'
half of the transcript, suggesting that alternative promoters in the middle of the gene may be used. SCC9 was chosen for further study because it expresses the 3' half of the
transcript at a level dramatically higher than normal for
oropharyngeal epithelium. Northern blotting detects a
comparatively abundant 6.4 kb truncated transcript as
well as smaller amounts of an 8.7 kb transcript in SCC9
(Figure 5A). The other three cell lines express their truncated CSMD1 transcripts at lower levels (data not shown).
Sequence analysis of CSMD1 cDNA clones from SCC9
demonstrates that many transcripts are improperly
spliced, resulting in retention of intronic sequences and/
or deletion of exonic sequences (data not shown). In par-

5' RACE [21] reveals that the SCC9 message is initiated
just upstream of an Alu element in intron 36 (Figure 5B).
Only the 5'-most 120 base pairs of the Alu element are
present in the genome. RT-PCR using a forward primer
specific for the novel sequences of the SCC9 transcript
(prm1904, cgtttagttcgacacacttcatgt) demonstrates that cell
lines 041, PCI-1 and PCI-2 do not initiate their CSMD1
transcripts at the same point, suggesting that other cryptic
promoters are active in these lines. The sequence of this
novel exon has been entered in Genbank as accession
number DQ093422.
DNA methyltransferase inhibitors activate the same
cryptic promoter used in cell line SCC9
Expression from epigenetically silenced promoters can
sometimes be restored by treatment with inhibitors of
DNA methyltransferase or histone deacetylase activity
([22]). We selected two low expressing cell lines with promoter methylation, UPCI:SCC104 and 094, for treatment
with various concentrations of 5-azacytidine or 5-aza-2'deoxycytidine (5-aza-dC) as well as combinations of
either of those drugs with the histone deacetylase inhibitor trichostatin A. These treatments did not reactivate the
silenced CSMD1 promoter. COBRA analysis of genomic
DNA from the treated cells suggested that the drugs did
not robustly affect methylation of the CSMD1 promoter
even at levels high enough to be toxic to the cells. These
experiments did however shed light on the cryptic promoter used in SCC9 cells and on the interpretation of
experiments using methyltransferase inhibitors.

Treatment of cell line 094 with relatively high doses of
5aza-dC results in the expression of the 3' end of the
CSMD1 transcript. This transcript was not detected in control 094 cells undergoing mock drug treatment (Figure 6)
nor was it detected in 094 cells growing under normal
culture conditions (data not shown). RT-PCR of cDNA
from drug-treated 094 cells using the primer developed
from the novel 5' exon of SCC9's truncated transcript
(prm1904, see above) yielded a product identical in size
to that amplified from SCC9 cDNA (Figure 6). The identity of the product was confirmed by DNA sequencing
which also revealed that the drug-induced 094 transcript
was more faithfully spliced than the transcript expressed
in SCC9 (data not shown).

Discussion
Our data clearly demonstrate that expression of normal
CSMD1 transcripts is rare in head and neck squamous cell
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Figure
A)
RT-PCR
4 demonstrating deletion of exons 4 and 5 from the CSMD1 transcripts of cell lines PCI-13 and UPCI:SCC066
A) RT-PCR demonstrating deletion of exons 4 and 5 from the CSMD1 transcripts of cell lines PCI-13 and UPCI:SCC066. RTPCR with a forward primer in exon 3 (prm2080, gggatttcagctgccctcctctat) and a reverse primer in exon 6 (prm1405, cttggaactgagcgttaaatcctttg) yields a 623 bp product from upper aerodigestive tract (UPPP), human fetal brain (HFB) and UPCI:SCC066
RNA. Exclusion of exons 4 and 5 from the transcripts of PCI-13 and UPCI:SCC066 reduces the size of the PCR product to 220
bp. The sizes of the DNA standards (STD) are indicated on the left side of the figure. The blank reaction contained water
instead of cDNA. "UPPP" = normal oropharyngeal epithelium isolated from uvulopalatopharyngoplasty surgical discards. B) Idiogram showing the organization of exons 3 through 6 in the human genome. The sizes of the introns were obtained from the
UCSC genome browser. The sequences of the splice junctions are provided above the idiogram with intronic bases in lowercase and exonic bases in uppercase. The structure of the UPCI:SCC066 and PCI-13 CSMD1 transcripts are shown below the
idiogram.
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A)
Figure
Northern
5
blot showing the truncated CSMD1 transcript expressed by the SCC9 cell line
A) Northern blot showing the truncated CSMD1 transcript expressed by the SCC9 cell line. Approximately 8 µg of poly-A+
RNA was fractionated on a denaturing 1% agarose gel, transferred to a filter and probed with the full length human CSMD1
cDNA. The image was acquired by phosphorimager scanning. B) Structure of the aberrant SCC9 transcript and the corresponding segment of the wildtype CSMD1 transcript showing the relationship between the novel cryptic promoter and exon
37. The partial Alu element contains only the first 120 base pairs of the normal ~300 bp Alu sequence.

carcinoma cell lines. Of the HNSCC cell lines examined,
only UPCI:SCC066 appears to express a normal transcript
from the expected promoter. Even that cell line produces
a second species of aberrantly spliced transcript lacking
internal exons. Our data suggest that epigenetic modification of the DNA 5' of the transcription start site may contribute to the down-regulation of CSMD1. In addition, a
low level of expression appears to be associated with production of prematurely terminated transcripts. This degree
of complexity might be expected from a 2 megabase, 70
exon gene.
Methylation of a specific region of the CpG island, -395 to
-112 bp relative to the transcriptional start site (amplicon

1), appears to be correlated with the activity of the normal
CSMD1 promoter. In contrast, methylation of amplicon
2, located within the first exon, shows no such relationship. Our data suggest that the relationship between the
amount of methylation in amplicon 1 and the level of
expression may not be strictly quantitative. Differences
between cell lines with amplicon 1 methylation could
arise through a number of mechanisms, for example, variations in the levels of transcription factors between cell
lines. In cases where there is considerable heterogeneity in
the methylation pattern within a cell line like PCI-100,
alleles with less methylation may be expressed at higher
levels than those more heavily methylated (compare
clones 51 and 52 to clone 58 in Figure 2C). Alternatively,
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ferase inhibitors. Detection of CSMD1 transcripts solely
with primers mapping to the 3' end of the gene could have
been erroneously interpreted as representing reactivation
of the normal promoter. It seems imperative that such
experiments demonstrate that transcripts detected after
drug treatment are actually initiated at the normal
promoter.

5aza-dC
promoter
Figure
6induced
active in
activation
cell line of
SCC9
CSMD1 from the same cryptic
5aza-dC induced activation of CSMD1 from the same cryptic
promoter active in cell line SCC9. Cultures of cell line 094
were treated with the indicated micromolar concentrations
of 5aza-dC, and used for RNA extraction. Cell line SCC9 was
grown in the absence of the drug and used as a control. RTPCR was performed with primers prm1904 (cgtttagttcgacacacttcatgt) and prm1880 (cactggaaggagagcacgtcgttcac).
prm1904 is specific for the cryptic first exon first used in
SCC9, prm1880 is homologous to CSMD1 exon 38. The
presence or absence of reverse transcriptase in the RT reaction is indicated by a + or -, respectively. The blank reaction
contained water instead of input cDNA. The sizes of the
markers are indicated on the left side of the figure.

the presence of methylation in amplicon 1 could be a
qualitative but not strictly quantitative indicator of methylation of a critical segment of the promoter not discovered in this study.
The normal CSMD1 promoter was not reactivated by
drugs that inhibit DNA methyltransferases and histone
deacetylases, nor did the drugs abolish CSMD1 promoter
methylation, even at toxic doses. Not all genes with promoter methylation respond to such treatments [23]. These
drug treatments did, however, provide a potential explanation for the use of a normally cryptic promoter by cell
line SCC9. The CSMD1 transcript in this line is initiated
near a partial Alu element. 5-aza-dC treatment of cell line
094 activates the same cryptic promoter. This suggests that
cryptic promoters may be naturally activated by general
hypomethylation of the genome in cancer cells and the
subsequent release of repetitive elements from epigenetic
repression (reviewed by Ehrlich [17]). The SCC9 transcript does not appear to encode a functional protein but,
with a very large gene like CSMD1, there is a potential for
some abnormally initiated transcripts to encode truncated
proteins with dominant negative properties.
The second ramification of this finding is for the interpretation of data obtained by treating cells with methyltrans-

Aberrant splicing also appears to play a role in the production of defective CSMD1 transcripts. Loss of splicing fidelity has been proposed as a characteristic of cancer cells
[24,25] and this would be consistent with the variety of
misspliced transcripts we detected from SCC9. However,
the removal of exons 4 and 5 from the CSMD1 transcript
in PCI-13 may reflect a more specific phenomenon than a
general inability to splice large introns; this line is still
capable of splicing large introns as evidenced by its successful splicing of exon 3 to exon 6, eliminating an intron
of over 666 kb. The failure to include exons 4 and 5 may
be due to inactivation of a splicing enhancer in intron 3,
or to less efficient splicing due to the fact that exons 4 and
5 do not begin with the consensus G residue (Figure 4B)
[26].

Conclusion
Taken together, our data suggest that CSMD1 function is
lost in head and neck squamous cell carcinoma cell lines
through a variety of mechanisms other than point mutagenesis. Epigenetic modifications of amplicon 1 and
defective splicing appear to be fruitful areas to explore in
primary head and neck squamous cancers.

Methods
Cell lines and tissue samples
DNA from HNSCC cell lines UMSCC9, UMSCC35,
UMSCC37,
UMSCC38,
UMSCC45,
UMSCC49,
UMSCC65, UMSCC68, and UMSCC76 was provided by
Dr. Thomas Carey, University of Michigan [27]. Dr. Ruud
Brakenhoff, Vrije Universitat, provided cell lines 040, 041,
and 094 [28]; Dr. Theresa Whiteside, University of Pittsburgh, provided cell lines PCI-1, PCI-2, PCI-4B, PCI-13,
PCI-30, PCI-50, PCI-51, PCI-52, PCI-100 [29], SCC4,
SCC9 [30,31], and UPCI:SCC068, UPCI:SCC74,
UPCI:SCC104, UPCI:SCC182, UPCI:SCC203, and
UPCI:SCC220 [developed by Dr. Susanne Gollin, University of Pittsburgh, 32]. Dr. Gollin provided cell lines
UPCI:SCC056, UPCI:SCC066, and UPCI:SCC114
[14,16,32]. The immortal but untransformed keratinocyte
line OKF6-TERT1 was obtained from Dr. James Rheinwald, Harvard University [20].

Normal oropharyngeal epithelium was isolated from discarded tissue from uvulopalatopharyngoplasties (UPPP)
collected anonymously with the approval of the Washington University Human Studies Committee.
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Cell Culture and Tissue Preparation
Squamous cell carcinoma cell lines were grown in DMEM
or DMEM:F-12, 1:1 Mixture (BioWhittaker) containing
10% fetal bovine serum (Sigma). DMEM medium was
supplemented with 1X MEM Nonessential Amino Acids
(BioWhittaker). Upper aerodigestive tract epithelium was
separated from the rest of the UPPP specimen by digestion
with Dispase II (Roche) using a protocol adapted from
Oda and Watson [33].
Nucleic acid preparation and bisulfite conversion
Genomic DNA was isolated by using either Nucleospin
Tissue kits (Clontech), QIAamp DNA Blood Mini kits
(Qiagen) or Trizol (Invitrogen) according to the manufacturers' instructions. Total RNA isolation, synthesis of first
strand cDNA, RT-PCR and 5' RACE PCR were performed
essentially as previously described [1]. Poly-A+ RNA for
Northern blotting was selected from total RNA using Oligotex beads (Qiagen). Northern blotting and hybridization were performed as previously described [1]. cDNA
synthesis was primed using oligo dT or random primers
and extended by either Thermoscript or Superscript III
reverse transcriptase (Invitrogen). PCR was run in PerkinElmer 480 or Applied Biosystems 9700 thermal cyclers for
35 cycles unless otherwise noted. Images of ethidium bromide stained gels were captured with a Gel-Doc imaging
station (Biorad). Quantitative PCR was run in an Applied
Biosystems 5700 thermal cycler using SYBR Green Master
Mix (Applied Biosystems). Primers prm2426 (gtgtggagtatctgcagacatga) and prm2427 (ctggactaagcctccacagttct)
were used to amplify a 132 base segment spanning
CSMD1's first and second exons. An amplicon from
human 18S RNA was used as a basis for comparisons
across cell lines (primers prm2396, ttcggaactgaggccatgat
and prm2397, tttcgctctggtccgtcttg). Calculations were performed using the ∆∆Ct method in GeneAmp 5700 SDS

software (version 1.3) and Microsoft Excel. Quantitation
was based on the average values obtained from duplicate
reactions. The level of CSMD1 expression in normal
oropharyngeal epithelium was determined from pooled
cDNA from five UPPP specimens.
We used the CpGenome DNA Modification kit (Intergen)
for bisulfite conversion of the genomic DNA according to
the manufacturer's protocol, with the following exception. Incubation of the conversion reaction was carried
out in a thermal cycler for six cycles each consisting of
three minutes at 94°C followed by three hours at 50°C
(Christina Menke and Paul Goodfellow, personal
communication).
Analysis of CSMD1 Promoter Methylation
Methylation of three segments of the CSMD1 CpG island
was examined using the Combined Bisulfite Restriction
Analysis technique (COBRA) [19]. All three segments
were amplified by using the nested primers and PCR conditions listed in Table 1. Amplicon 1 extends from -395 to
-112 bp, amplicon 2 from +175 to +396 bp, and amplicon
3 from +398 to +718 bp relative to the first base of the
transcript. A small region surrounding the transcription
start site (-111 to +174 bp) could not be examined
because no PCR primers could be designed from its
extremely GC-rich sequence. The first round PCR used 2
µl of bisulfite converted genomic DNA in a final volume
of 10 µl. Subsequent amplifications with nested primers
used 4 µl of first round product as template in reactions
with a final volume of 20 µl. All PCR was carried out for
35 cycles. A portion of the second round PCR product was
run on a 1.5% agarose gel, stained with ethidium bromide, and quantified using the ImageQuant software
package (v1.2 for Macintosh, Molecular Dynamics) so
that equal amounts of each could be used in restriction

Table 1: PCR primers used for COBRA analysis of CSMD1 CpG island

PCR round

forward

reverse

Amplicon
1
1 st

prm1998

taagttaggtagggggttgtttt

prm1999

2 nd

prm2000

ggaagggagattaaaggatgg

prm2001

Amplicons
2 and 3
1 st

prm1942

gagtagtttagttttgtagtggt

prm1943

2 nd

prm2006

agtagtttagttttgtagtggtt

prm2007

2 nd

prm1954

tgtggagtatttgtagatatgattg

prm1968

aaccactacaaaactaa
actact
aaactcaaccatccttac
ccacaa

tattaaattcctttctcct
taaca
caatcatatctacaaata
ctcc
cctttctccttaacaccc
tatacta

annealing
temp

[MgCl2]
(mM)

amplicon
size (bp)

# of
CpG's

# BstU1
sites

# Taq1
sites

45°C

1.5

626

58°C

1.5

298

19

1

4

45°C

2.0

594

45°C

2.0

225

20

2

1

55°C

1.5

388

31

4

1
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digests.
Restriction digests for COBRA were performed with either
BstU I or Taqα I (5 or 10 units per reaction, respectively;
New England Biolabs) for 4 hours in a final volume of 10
µl. Taqα I digests were performed only when no methylation was detected with BstU I. BstU I digests also included
an internal control DNA fragment to confirm complete
digestion. This DNA fragment contains a single BstU I site
and was amplified from a cloned CSMD1 cDNA using
primers prm2020 (agatcccccagtgtctccctgtgt) and prm2021
(actgctggtgccgtggtaatgact). The control PCR product is
1019 bp long and is digested to two fragments of 605 and
414 bp by BstU I. Digestion products were fractionated on
a 10% polyacrylamide gel, stained with ethidium
bromide, and visualized with a Gel-Doc video imaging
workstation (Bio-Rad).
High resolution analysis of methylation was performed
by sequence analysis of individual clones from amplicons
1 and 2. DNA from amplicon 3 proved unclonable and gel
electrophoresis suggests that its very AT rich sequence
results in a bent DNA configuration. PCR products were
purified using the Nucleospin Extraction columns (Clontech) and inserted into the pCR2.1-TOPO vector using the
TOPO TA Cloning kit (Invitrogen) according to the manufacturer's instructions. Plasmid DNA from individual
colonies was isolated using the Nucleospin Plus Plasmid
Miniprep kit (Clontech) and sequenced with a reverse vector primer (agcggataacaatttcacacagga) using fluorescence
based sequencing with Big Dye Terminator mix (Applied
Biosystems).
Treatment of cultured cells with DNA methyltransferase
inhibitors
Cell line 094 was treated with 5-aza-2'-deoxycytidine
(5aza-dC) (Sigma) dissolved in DMSO. Two 100 mm cell
culture dishes containing 5 × 105 cells were established for
each of the drug concentrations tested. Cells were grown
for 72 hours in media containing DMEM:F-12, 1:1 Mixture (BioWhittaker) with 1X MEM Nonessential Amino
Acids (BioWhittaker) and 10% fetal bovine serum and
then switched to media containing 5aza-dC at concentrations of 0 µm, 5 µM, 25 µM, or 100 µM. Cells were fed
daily for 4–5 days and then both plates were harvested in
3 ml of Trizol (Invitrogen) for isolation of RNA and DNA
according to the manufacturer's instructions. RT-PCR
used for detection of CSMD1 transcripts in these treated
cells was run for 40 cycles.

Abbreviations
5aza-dC = 5-aza-2'deoxycytidine, COBRA = Combined
Bisulfite Restriction Analysis, CSMD1 = Cub and sushi multiple domains 1, HNSCC = head & neck squamous cell carcinoma, RT-PCR = reverse transcription – polymerase

http://www.cancerci.com/content/5/1/29

chain reaction, SCC = squamous cell carcinoma, UPPP =
uvulopalatopharyngoplasty.
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